Drug intelligence / Profile preview

Qiangxin Compound

Development stage: Unknown
Lead developer: Yiling Pharmaceutical
Administration: Oral

Overview

Qiangxin Compound is a Traditional Chinese Medicine (TCM) formulation currently in clinical development for the treatment of type 2 cardiorenal syndrome. It is being investigated as part of an integrated Chinese and Western medicine management approach. Developed by the Traditional Chinese Medicine Hospital of Shanghai, this compound is expected to exert a cardiotonic effect, aiming to strengthen heart function through a multi-component and multi-target mechanism of action, typical of TCM formulations.

Other names: 强心方

Beyond the preview

Go deeper on Qiangxin Compound.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qiangxin Compound.

Explore the full profile